Ensysce Biosciences, Inc. filed definitive additional proxy materials on November 18, 2026, supplementing its proxy statement for the Annual Meeting of Stockholders scheduled for December 14, 2026, to disclose a Nasdaq minimum bid price deficiency and clarify broker discretionary voting authority on Proposal 2.

Key Highlights

  • Nasdaq non-compliance: The company disclosed it is not in compliance with Nasdaq's minimum bid price requirement of $1.00 per share for its common stock.
  • Deadline granted: By letter dated August 25, 2026, Nasdaq granted the company additional time, to February 22, 2027, to regain compliance with the minimum bid price requirement.
  • Reverse stock split ratio: Proposal 2 seeks approval of a reverse stock split at a ratio of not less than one-for-ten and not more than one-for-thirty, with the exact ratio to be set by the Board.
  • Initial listing threshold: To satisfy Nasdaq's initial listing requirement triggered by a change-of-control determination, the company stated it may need a minimum bid price of $4.00 per share before converting Series C Preferred Stock into common stock.
  • Staged meeting possible: The company disclosed it may conduct the Annual Meeting in stages, voting first on Proposal 2 and then adjourning for remaining proposals.
  • Broker discretion correction: The supplement corrects the prior proxy statement, disclosing that brokers will have discretionary voting authority on Proposal 2 for shares held in street name, contrary to what the original proxy stated.
  • Record date unchanged: The record date remains the close of business on November 10, 2026.

Ensysce Discloses Nasdaq Deficiency and Staged Meeting Plan Ahead of December 14 Annual Meeting

According to the filing, Ensysce Biosciences, Inc. (NASDAQ:ENSC) submitted this supplement to its proxy statement, originally filed on Schedule 14A on November 12, 2026, in connection with its Annual Meeting to be held virtually on December 14, 2026, at 9:00 a.m. Pacific time. The supplement adds disclosures that were absent from the original proxy regarding the company's standing with Nasdaq's continued listing standards.

The filing states that Nasdaq advised the company by letter dated February 25, 2026, that it was not in compliance with the minimum bid price requirement of $1.00 per share. A subsequent letter dated August 25, 2026, extended the compliance deadline to February 22, 2027, and, according to the filing, "Nasdaq has generally viewed a near-term reverse stock split as the only acceptable plan to regain compliance." The company stated it "remains noncompliant" and "believes that we must effect this proposal (Proposal 2) to raise the bid price above $1.00 to avoid delisting." The filing also notes that Nasdaq determined approval of Proposal 1 constitutes a change of control under Nasdaq Listing Rules 5110(a) and 5635(b), requiring the company to satisfy Nasdaq's initial listing requirement of a minimum bid price of $4.00 per share before converting Series C Preferred Stock into common stock.

The supplement also corrects a material point from the original proxy: brokers holding shares in street name will have discretionary voting authority on Proposal 2 even without client instructions, reversing the prior statement that brokers had no such authority. The company confirmed the Annual Meeting remains scheduled as previously announced, that no new proxy card will be distributed, and that previously submitted proxies remain valid unless shareholders choose to change their votes prior to the meeting.

What Was Disclosed

Ensysce Biosciences filed supplemental proxy materials disclosing a Nasdaq bid price deficiency, a compliance deadline of February 22, 2027, the possibility of a staged annual meeting, and a correction to broker discretionary voting authority on the reverse stock split proposal.